5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
Enabling every cure for community matters: Our AI-powered journey
As we move through 2024, I’m thrilled with the extraordinary work our team is doing to change how we finance drug development: from funding next-generation therapies to helping others identify the highest potential cures in their development pipelines.
Revolutionizing Drug Development for Rare Diseases Through AI | Alok Tayi
“In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases with unmet needs, leveraging AI to find medicines with the highest chances of providing cures.”
Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.
The Impact Review – Founding Vibe Bio
The Impact Review article explores Alok Tayi’s personal experience with rare disease drove him towards a mission – to fund cures for rare diseases.
The Biotech Startups Podcast with guest Alok Tayi, Founder & CEO of Vibe Bio
Learn how Vibe Bio is tackling the problem of funding & guiding high potential drug programs.
Forbes – Alok Tayi’s new start-up is putting drug development into patients’ hands
This article examines how Vibe Bio’s Founder and CEO is putting drug development into patients’ hands.
